PTEN mutation

While several molecular alterations show compelling biological rationale and encouraging clinical signals, few biomarkers have achieved prospective validation sufficient for routine implementation. The next phase of progress will depend on biomarker-enriched trial designs, harmonized testing strategies, and integration of multi-omic profiling to overcome biological heterogeneity and therapeutic resistance.

SM exhibits temporal, histologic, and molecular distinctions across primary sites. Response to front-line therapy and survival outcomes are poor. Future direction includes the exploration of underlying predictors of transformation and identification of targetable alterations in the relapsed setting.

Collectively, the data support a shift from single-analyte biomarkers toward integrative, dynamic, systems-level models for patient selection, heralding a new era of precision immune-oncology in GC. However, most emerging biomarkers remain investigational and require prospective validation.

scRNA-seq analysis suggests roles of epithelial-mesenchymal transition in the progression from carcinoma cells to sarcomatoid cells and in immunotherapy resistance in PSC. Altogether, this multi-omics characterization of PSC serves as a rich resource for investigating mechanistic insights and identifying potential therapeutic targets.

Lastly, while structural variants can disrupt TAD, PTEN mutations alone only slightly reinforce intra-TAD contacts without changing the structure. These findings provide the first high-resolution map of PTEN enhancer hubs, reveal new principles of enhancer cooperation and long-range gene regulation, and delineate candidate regions whose disruption may contribute to PHTS and PTEN-driven tumorigenesis.

Immunohistochemistry confirmed hallmark features of EMT in the uterus of double-mutant mice, including strong downregulation of E-cadherin (CDH1) and upregulation of the EMT regulator SNAIL (Snai1). These findings demonstrate that synergistic mutations of PTEN and CTNNB1 promote early invasion, EMT activation, and metastatic progression, offering mechanistic insight into the aggressive behavior and poor clinical outcomes associated with this subtype of EEC.

Furthermore, static magnetic fields have been reported to increase apoptosis, inhibit proliferation, and may offer a complementary treatment with low toxicity. These findings suggest that magnetic-field-based approaches offer an innovative strategy for GBM treatment.

Future integration with multi-omics data, radiomics, and artificial intelligence (AI) promises to enhance its clinical utility. Overcoming current hurdles through standardization and technological innovation is essential for its routine clinical adoption.

A transcriptional signature associated with SARM sensitivity was identified, primarily driven by proliferation-related processes, consistent with a significant decrease in S-phase cell cycle proteins upon treatment in EP0062-sensitive models. In some EP0062-resistant tumors, the combination with palbociclib enhanced the antitumor effect of EP0062, suggesting a potential strategy for metastatic patients with acquired ET resistance.

Notably, low-dose Capivasertib, an AKT inhibitor targeting tumors with PIK3CA/AKT1/PTEN mutation(s), induced senescence selectively in FUCA2-high LUAD irrespective of PIK3CA/AKT1/PTEN/TP53 mutational status, and its combination with the nutraceutical senolytic procyanidin C1 achieved potent and low-toxicity suppression of LUAD across multiple preclinical models. Together, our results uncover the FUCA2-ErbB3 fucosylation-AKT pathway as a central regulator of senescence and propose a FUCA2-guided drug repurposing strategy for LUAD.

P1, N=23, Recruiting, Deborah Doroshow | Trial completion date: Dec 2027 --> Jul 2028

Recent developments in personalized medicine, including the introduction of new molecular diagnostic tools and targeted agents, have made considerable progress in the risk stratification and treatment strategies for papillary thyroid carcinoma. The current article reviews molecular mechanisms of activation of MAPK and PI3K/AKT pathways, their interaction, clinicopathological importance, and targeted treatments in papillary thyroid carcinoma.